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Abstract
Tau proteins are abnormally aggregated in a range of neurodegenerative tauopathies
including Alzheimer’s disease (AD). Recently, tau has emerged as an extensively post-
translationally modified protein, among which lysine acetylation is critical for normal tau
function and its pathological aggregation. Here, we demonstrate that tau isoforms have dif-
ferent propensities to undergo lysine acetylation, with auto-acetylation occurring more
prominently within the lysine-rich microtubule-binding repeats. Unexpectedly, we identified
a unique intrinsic property of tau in which auto-acetylation induces proteolytic tau cleavage,
thereby generating distinct N- and C-terminal tau fragments. Supporting a catalytic reac-
tion-based mechanism, mapping and mutagenesis studies showed that tau cysteines,
which are required for acetyl group transfer, are also essential for auto-proteolytic tau pro-
cessing. Further mass spectrometry analysis identified the C-terminal 2nd and 4th microtu-
bule binding repeats as potential sites of auto-cleavage. The identification of acetylation-
mediated auto-proteolysis provides a new biochemical mechanism for tau self-regulation
and warrants further investigation into whether auto-catalytic functions of tau are implicated
in AD and other tauopathies.
Introduction
Tau proteins are expressed primarily in the nervous system and are comprised of six isoforms
containing up to two N-terminal repeats (0N, 1N, or 2N) and either three (3R-tau) or four
(4R-tau) repeat domains that contribute to tau-microtubule (MT) binding, thereby regulating
MT stability [1, 2]. We and others previously demonstrated that tau is extensively acetylated
on lysine residues mainly residing within the MT-binding repeats (MTBR), thus providing a
novel regulatory modification controlling normal and abnormal tau properties [3–5]. Func-
tional studies showed that tau acetylation impaired normal tau-MT interactions, prevented
physiological tau-mediated stabilization of MTs, and altered pathological tau fibril formation
that is predominantly associated with insoluble, Thioflavin-positive tau aggregates [3, 5].
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Indeed, the disease relevance of tau acetylation was demonstrated in neuropathological and bio-
chemical analysis of a panel of human tauopathy cases. Acetylation at residue K280 (Lys280)
showed a distinctly pathological signature marking mature tau lesions in Alzheimer’s disease
(AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and several
FTDP-17 familial cases of dementia [3] but was rarely observed in control brain tissue or cultured
wild-type cells or neurons [4], illustrating the disease-specific nature of K280 acetylation.
More recently, tau acetylation at other critical residues including K174, K274, and K281 has
been shown to promote AD-related cognitive deficits, synaptic defects, and impaired hippo-
campal long-term potentiation (LTP) [6, 7], strongly implicating tau acetylation in AD patho-
genesis. While the specific pathogenic signaling pathways mediated by acetylated tau are
emerging [7], the relationship of tau acetylation to other disease-associated tau modifications
(e.g. phosphorylation, ubiquitination, and proteolytic cleavage) is not well understood. How-
ever, previous in vitro studies as well as proteomic analysis in mouse brain suggests a global tau
acetylation profile that overlaps with known sites of tau ubiquitination [5, 8], implying PTM
competition could dictate tau function. Ongoing efforts to dissect tau post-translational pro-
cessing could provide a step-wise framework for tau pathogenesis.
While previous studies have suggested tau acetylation occurs in trans by Creb-binding pro-
tein (CBP/p300) and possibly other yet-to-be-identified acetyltransferases [3, 5, 9, 10], evidence
also indicates that tau auto-acetylation can occur upon incubation of tau proteins with acetyl-
CoA alone. Indeed, many acetyltransferases control their own catalytic activity via positive
feedback auto-acetylation [11–16]. We proposed that tau utilizes a cysteine-mediated acetyl
group transfer onto its lysine residues [9], which is consistent with the mechanism proposed
for MYST and N-arylamine (NAT) acetyltransferases [17, 18], to which tau has some func-
tional and sequence similarities [9]. This acetyl transfer mechanism from cysteine to lysine res-
idues contrasts with previously reported non-specific acetylation of cysteines observed with in
vitro peptide substrates, which can often lead to false positive assignments of lysine acetylation
[19]. Supporting cysteine-mediated tau auto-acetylation, a recent molecular simulation study
of tau suggested close cysteine-lysine distances that could facilitate self-acetylation [20].
Remarkably, a recent profiling study indicated that auto-acetylation of cellular proteins could
even occur in the apparent absence of enzymatic activity [21], in which case lysine specificity
may be dictated by lysine accessibility and/or specific lysine pKa values. Such non-enzymatic
auto-acetylation is a prominent feature of mitochondria localized proteins, where acetyl-CoA
levels are highly enriched [22–24].
We investigated the impact of tau acetylation using recombinant tau proteins with a variable
number of N-terminal inserts or C-terminal MTBR domains. Surprisingly, we found that auto-
acetylation occurs within the MTBR region, while CBP-mediated acetylation occurs both
within the MTBR and also distally in the proline-rich region. To assess the regulatory function
of tau auto-acetylation, in vitro assays revealed an unexpected auto-proteolytic cleavage event
dependent on tau catalytic cysteine residues (C291/C322) residing within the MTBR, leading
to the production of distinct N- and C-terminal tau fragments. Our study suggests that tau
auto-acetylation may be coupled to downstream self-degradation mechanisms, which could be
relevant to AD and related tauopathies characterized by tau hyper-acetylation and pathological
cleavage fragments.
Materials and Methods
Plasmids and Cell Culture
All human tau isoforms containing 0, 1, or 2 N-terminal inserts and either 3 or 4 MTBR
regions were cloned into pCDNA5/TO vector (Invitrogen) and site-directed mutagenesis
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(Quikchange kit; Agilent, Santa Clara, CA) was used to create cysteine mutations at residues
C291 and C322, where indicated. A mammalian expression plasmid containing wild-type CBP
or the inactive L1435A/D1436A mutant (pcDNA3.1-CBP and CBP-LD) were kindly provided
by Dr. Tso-Pang Yao (Duke University). All described plasmids were transfected into QBI-293
cells using Fugene (Roche) or Lipofectamine 2000 (Life Technologies) per the manufacturers
detailed protocols.
Biochemical extraction of cultured cells
Fractionation of all cell lysates was performed by sequential extraction using buffers of increas-
ing strength. Cells from 6-well culture dishes were scraped into 300 μl RIPA buffer (50 mM Tris
pH 8.0, 150 mMNaCl, 1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS) contain-
ing 1 mM phenylmethylsulfonyl fluoride (PMSF), a mixture of protease inhibitors (1 μM pepsta-
tin, leupeptin, N-p-Tosyl-l-phenylalanine chloromethyl ketone, Nα-Tosyl-l-lysine chloromethyl
ketone hydrochloride, trypsin inhibitor; Sigma), and a mixture of phosphatase inhibitors (2 mM
imidazole, 1 mMNaF, 1 mM sodium orthovanadate; Sigma). Samples were sonicated and centri-
fuged at 100,000xg for 30 min at 4°C, and then re-extracted in RIPA buffer to ensure complete
removal of soluble proteins. Resultant insoluble pellets were extracted in 100 μl urea buffer (7 M
urea, 2 M Thiourea, 4% CHAPS, 30 mMTris, pH 8.5) containing the same formulation of inhibi-
tors as described for RIPA buffer, then sonicated and centrifuged at 100,000xg for 30 min at
room temperature. Soluble and insoluble fractions were analyzed by western blotting using the
indicated antibodies. Tau antibodies used for western analysis were as follows: C-terminal T46
(1:1000, Thermofisher), tau-5 (1:1000, Thermofisher), tau-1 (1:1000, Thermofisher), K9JA
(1:10,000, Dako), ac-K280 [3] (1:1000), and ac-K163 (1:1000, this study).
Recombinant tau in vitromethods
Tau protein preparations. All full-length (0N4R, 1N4R, 2N4R, 0N3R, 1N3R, 2N3R), tau-
K18 (4R), and tau-K19 (3R) proteins were purified using an AKTA-Pure FPLC chromatogra-
phy system (GE). The proteins were expressed in Escherichia coli BL21(DE3) RIL strain. Bacte-
ria were grown in LB media containing ampicillin at 37°C and induced with isopropyl-D
-thiogalactopyranoside at a final concentration of 0.8 mM when the OD reached 0.6. After agi-
tation for 2 h, cells were harvested by centrifugation. The pellet was re-suspended in high-salt
RAB buffer [0.1 MMES, 1 mM EGTA, 0.5 mMMgSO4, 0.75 M NaCl, 0.02 M NaF, 0.1 mM
PMSF, 0.1% protease inhibitor cocktail (100 μg/mL each of pepstatin A, leupeptin, TPCK,
TLCK, and soybean trypsin inhibitor and 100 mM EDTA), pH 7.0] and homogenized. The cell
lysates were heated to 100°C for 10 min, rapidly cooled on ice for 20 min and centrifuged at
70,000xg for 30 min. Supernatants were dialyzed into FPLC buffer A [20 mM piperazine-N,
N-bis(2-ethanesulfonic acid) pH 6.5, 10 mM NaCl, 1 mM EGTA, 1mMMgSO4, 2 mMDTT,
0.1 mM PMSF], applied onto a HiTrap Sepharose HP IEX cation-exchange column (GE
Healthcare), and eluted with a 0–0.4 M NaCl gradient using an AKTA-Pure FPLC system (GE
Healthcare). The fractions were checked for the presence of the tau proteins by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS- PAGE) followed by Coomassie Blue R-250
staining. The fractions containing enriched purified tau were pooled together and dialyzed
against 100 mM sodium acetate buffer, pH 7.0. Importantly, all purified tau proteins were
subject to a critical heat-denaturation step for 30 min at 100° to inactivate any endogenous bac-
terial enzymes and simultaneously enrich for heat-stable tau proteins. Proteins were concen-
trated using Amicon Ultra centrifugal filter units (Millipore Corporation, Billerica, MA), and
protein concentrations were determined using the bicinchoninic acid protein assay (Pierce,
Rockford, IL) with bovine serum albumin as the protein standard.
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In vitro acetylation reactions. Tau K18 or full-length tau proteins were either mock acety-
lated with coenzyme A alone or modified in vitro using acetyl-CoA, butyryl-CoA, or propio-
nyl-CoA (Sigma) in acetylation reaction buffer (50 mM Tris–HCl pH 8.0, 10% glycerol, 1 mM
DTT, 100 μM EDTA, 1 mM PMSF, 0.4 mM CoA derivative) at 37°C for the indicated time-
points from 1 day—7 days. Purified recombinant CBP protein (Enzo Life Sciences) (0.5 ug)
was incubated in the acetylation reactions, where indicated, leading to maximal tau acetylation.
Reaction products were analyzed by resolving proteins on 15% SDS-PAGE gels followed by
Coomassie staining or subsequent immunoblotting with the indicated tau antibodies, where
indicated. For tau pharmacological inhibition studies, tau proteins were pre-incubated on ice
with 100 μM chymostatin, 1 mMN-ethylmaleimide (NEM), 4mM iodoacetamide (IA), 10 μM
ALLN, and 10 μMAntipain (Sigma) followed by the above described acetylation reactions. All
reactions were performed with a minimum of N = 3 independent experimental replicates. For
tau fragmentation studies, error bars represent standard deviation (SD) among replicates and
statistical calculations were performed using student t-test with significant p-values 0.01.
In vitro calpain reactions. Calpain protease digestions were performed using 20 μM
recombinant tau (2N4R) and increasing concentrations of 0–0.5 Units recombinant calpain-2
(Millipore) and incubated at 30° for 10-min in calpain reaction buffer (50mM Tris, pH 7.5,
2mM DTT, 1mM EDTA, 100mMNaCl, 3mM CaCl2) followed by 5-min heat denaturing at
95° in SDS sample buffer and analysis of N- and C-terminal tau epitopes by immunoblotting.
Mass spectrometry. NanoLC nanospray MS-MS analysis was performed at the University
of Pennsylvania proteomics core facility, which identified butyrylated and propionylated lysine
residues. Total tau proteins (1μg total protein) and 0.4 mM butyryl or propionyl-CoA were
incubated in 30 μl of reaction buffer (50 mM Tris-HCl pH 8.0, 10% glycerol, 1 mM DTT, 100
mM EDTA, 1 mM phenylmethylsulfonyl fluoride) for 1 hr at 37°C. Acylated tau products were
analyzed by SDS-PAGE and Coomassie staining followed by gel excision for mass spectrome-
try using LTQ XL Linear Ion Trap Mass Spectrometer (Thermo Scientific). Data was acquired
using Xcalibur software (Thermo Scientific) and analyzed using Mascot, Scaffold, and PEAKS
softwares.
Size-exclusion Chromatography (SEC)
SEC was performed using an Acquity UPLC system equipped with a photodiode array detector
(Waters Corp., Milford, MA). Injections of 15 μl were separated with an Acquity BEH200 SEC
1.7 μm (4.6 × 300 mm including a 4.6 × 30 guard column) using 100 mm sodium acetate, pH 5,
with 300 mm NaCl at 0.3 ml/min over 30 min. Sample peaks were detected and analyzed using
absorbance at 220 nm.
Peptide/Antibody generation
Polyclonal anti-acetyl tau K280 antibodies were previously described [3]. Anti-acetyl tau K163
antibodies were generated using the acetylated tau peptide C-PGQKGQA containing K163
chemical acetylation to immunize rabbits (Pocono Rabbit Farm and Laboratory Inc., Canaden-
sis, PA). Double affinity purification was performed using native and acetylated peptides
sequentially using Sulfolink columns (Pierce Biotechnology). Site specificity of ac-K163 was
confirmed using a K163R mutant tau that was unable to become fully acetylated in the pres-
ence of CBP (Fig 1).
Brain tissue extraction and analysis
All brain tissue was acquired from the Center for Neurodegenerative Disease Research
(CNDR) at the University of Pennsylvania brain bank. Frontal cortex from control and Braak
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Fig 1. Tau isoforms display distinct patterns of acetylation at lysine residues K163 and K280. A) A schematic of the tau protein is shown depicting the
microtubule-binding region (MTBR) and the proline-rich domain containing previously identified sites of tau acetylation.B)QBI-293 cells co-transfected with
CBP and either WT or K163Rmutant versions of 2N4R-tau were fractionated into RIPA soluble (S) and insoluble (I) fractions followed by immunoblotting with
ac-K163 and K9JA antibodies. C)QBI-293 cells were transfected with 2N4R, 0N4R, or 0N3R expressing tau plasmids and cell lysates were immunoblotted
using ac-163, ac-K280, and total tau K9JA antibodies. A six tau isoform ladder (lane 1) was included as a tau molecular weight marker and negative control,
which showed no immunoreactivity with either acetylated tau antibody, as expected.D) Recombinant full-length tau isoforms (2N4R, 0N4R, 0N3R) were
acetylated by incubation with acetyl-CoA in the presence or absence of CBP. Reaction products were subjected to immunoblot analysis using the
acetylation-specific antibody against residue K163 (ac-K163) or K9JA to detect total tau proteins. E) Recombinant full-length tau 2N4R-tau was similarly
Tau Acetylation Promotes Fragmentation
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stage VI Alzheimer’s disease cases were used to prepare gray matter, which was homogenized
in 3 vol/g of cold High Salt RAB buffer (.75 M NaCl, 100 mM Tris, 1 mM EGTA, 0.5 mM
MgSO4, 0.02 M NaF, 2 mM DTT, pH 7.4). All buffers were supplemented with protease inhibi-
tor cocktail, phosphatase inhibitor, and HDAC inhibitors (2 uM Trichostatin A and 10 mM
nicotinamide). The high-salt RAB homogenates were incubated at 4° C for 20 min to depoly-
merize MTs, then centrifuged at 100,000 xg for 30 min at 4° C to yield the high-salt (HS) super-
natant fraction. Pellets were re-homogenized and centrifuged in 3 vol/g of cold High Salt RAB
buffer. Resultant pellets were homogenized in 3 vol/g RIPA buffer (50mM Tris pH 8.0, 150mM
NaCl, 1% NP-40, 5mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS) and centrifuged at
100,000g for 30min followed by another RIPA extraction containing 20% sucrose, thus allow-
ing myelin floatation. Finally, the resultant insoluble pellets were extracted in 1 vol/g tissue in
urea buffer (7M urea, 2M Thiourea, 4% CHAPS, 30mM Tris, pH 8.5). Tau proteins present in
soluble high-salt (HS) and insoluble urea fractions were analyzed by SDS-PAGE electrophore-
sis and western blotting using tau-5, T46, and K9JA antibodies to detect total tau protein frag-
mentation patterns.
Results
Distinct tau acetylation patterns are observed within the MTBR
compared to the adjacent proline-rich region
Cell culture analysis previously identified lysines 163, 280, 281, and 369 as major sites of
human tau acetylation (see lysines highlighted in Fig 1A schematic). One of these sites, K163,
is localized to the tau proline-rich domain and is present in all 6 tau isoforms expressed in
human brain. Recent mass spectrometry analysis identified K163 as a prominent site of acetyla-
tion in vitro, in cultured cells, and in wild-type mouse brain [3, 5, 8]. Therefore, given the
potential significance of K163 acetylation, we sought to generate an acetylation-specific poly-
clonal tau antibody against a tau peptide antigen containing acetylated residue K163 (termed
ac-K163). Double-affinity purification with unmodified and chemically acetylated K163 pep-
tides was employed to enrich for the acetylation-specific antibody pool. We confirmed the site
specificity of the ac-K163 antibody by transfecting tau into QBI-293 cells, a cell line that lacks
any endogenous tau protein and therefore is amenable to antibody specificity analysis using
ectopically expressed tau proteins. Wild-type non-acetylated 2N4R-tau showed no immunore-
activity with ac-K163 under any conditions analyzed, however, tau was readily acetylated at
K163 in the presence of ectopically co-expressed CBP, confirming that ac-K163 recognizes
acetylated tau (Fig 1B, lane 1). Importantly, 2N4R-tau containing a K163R mutation abolished
ac-K163 immunoreactivity (Fig 1B, lane 3), highlighting the site-specificity of ac-K163 for the
targeted K163 residue.
We further tested ac-K163 immunoreactivity by western analysis using additional tau iso-
forms that were expressed in the absence or presence of CBP. All tau proteins analyzed were
only ac-K163 immunoreactive in the presence of CBP (Fig 1C). Surprisingly, we observed an
isoform-specific acetylation pattern, in which 0N4R tau proteins lacking the N-terminal inserts
were more strongly ac-K163 immunoreactive compared to other 3R and 4R tau isoforms (Fig
incubated in acetylation reactions containing acetyl-CoA and/or CBP and reactions products were analyzed by immunoblotting with ac-K280 and K9JA
antibodies. Ac-K163 and ac-K280 immunoreactivity was quantified, where indicated, using densitometry readings of acetylated tau protein bands. The
percentage of acetylated tau was normalized to total tau and represented as a ratio of acetylated tau/total tau. F) In vitro acetylation reactions were performed
similar to (E) above using tau-K18 (MTBR only) and tau-ΔK18 (full-length tau lacking the 4-repeats) incubated in the presence of purified CBP, where
indicated, along with radiolabeled [14C]-acetyl-CoA. Acetylation reactions were analyzed by SDS-PAGE and Coomassie staining followed by
autoradiography using STORM phosphorimager software to visualize acetylated tau protein bands.
doi:10.1371/journal.pone.0158470.g001
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1C, lane 5). In contrast, acetylation at residue K280 showed no apparent differences in immu-
noreactivity among the 4R-tau isoforms analyzed, as both 2N4R and 0N4R isoforms were simi-
larly immunoreactive with ac-K280.
In vitro assays using recombinant, purified tau proteins in the presence of acetyl-CoA and
CBP confirmed CBP-dependent K163 acetylation. Similar to the above cell-based results, puri-
fied 0N4R-tau proteins were strongly acetylated at K163 in the presence of CBP, but not upon
incubation with acetyl-CoA alone, implying that little detectable auto-acetylation occurs at this
distal acetylation site localized to the proline-rich region (Fig 1D, lanes 4–6). In vitro acetyla-
tion at K163 was less abundant using 3R-tau proteins compared to 4R-tau proteins, suggesting
that MTBR repeats influence more distal acetylation at residue K163 (Fig 1D, lanes 7–9). Also
similar to the cell-based assay, N-terminal inserts were inhibitory towards in vitro acetylation
at K163, since among the 4R-tau isoforms tested the strongest ac-K163 immunoreactivity was
observed with 0N4R tau (Fig 1D, compare lanes 3 and 6). In contrast, residue K280 showed
mild auto-acetylation within the MTBR, as indicated by ~ 25% ac-K280 immunoreactivity in
the presence of acetyl-CoA alone, which was strongly induced by the addition of purified CBP,
as expected (Fig 1E).
To confirm the preferential auto-acetylation within the MTBR, a tau-K18 fragment com-
prising only the 4-repeat region itself (~15 kDa fragment) was strongly auto-acetylated in the
presence of radiolabeled [14C]-acetyl-CoA (Fig 1F, lane 1), however, a full-length tau fragment
lacking all 4 repeats (referred to as ΔK18, ~35 kDa fragment) was only acetylated in the pres-
ence of CBP (Fig 1F, compare lanes 2–4). Notably, ΔK18 was unable to be acetylated in trans in
the presence of K18, suggesting predominantly cis auto-acetylation, consistent with our previ-
ous study [9]. Thus, CBP non-selectively acetylates tau within the proline-rich and MTBR
regions (e.g. both K163 and K280), while tau auto-acetylation occurs prominently within the
lysine-rich MTBR (e.g. K280). Given the unique auto-acetylation properties of tau, we sought
to further explore the consequences of this potentially critical auto-regulatory mechanism.
Tau auto-acetylation promotes tau proteolytic degradation
We next examined the effects of in vitro tau auto-acetylation on tau fragmentation. Previous stud-
ies of bacterial acetyltransferases have hinted that auto-acetylation could be coupled to down-
stream post-translational processing including proteolysis [25]. Full-length 0N4R or tau
containing only the repeat region (tau-K18) were auto-acetylated with acetyl-CoA or incubated
with a CoA control for up to 7 days in vitro. Surprisingly, we noticed that acetyl-CoA, but not
CoA, led to progressive fragmentation of tau-K18 into low molecular weight (LMW) species that
were< 10 kDa (Fig 2A, lanes 1–2). Similarly, auto-acetylation of full-length 0N4R tau proteins
led to production of distinct tau fragments, however, in contrast to low molecular weight smear-
ing, full-length 0N4R-tau generated distinct ~ 43, 38, 17 and 12 kDa tau fragments (Fig 2A, lanes
3–4, see fragments depicted by arrows). Quantification of these results showed a ~ 10-fold increase
in tau-K18 fragmentation (Fig 2B), while 0N4R-tau acetylation led to a mild but significant reduc-
tion in full-length protein that coincided with the accumulation of tau fragments (Fig 2C). A
time-course analysis indicated that tau-K18 fragments were robustly detected by 1 day incubation
in vitro, with a small increase in fragmentation thereafter up to 7 days (Fig 2D and 2E).
To confirm that auto-acetylated tau generates bona fide truncation fragments, size-exclu-
sion chromatography (SEC) was employed to detect more slowly eluting low molecular weight
tau fragments (Fig 2F). SEC analysis of either untreated or CoA treated 0N4R-tau reactions
showed a single prominent full-length tau protein peak eluting at ~ 7.70 min with no apparent
smaller molecular weight tau peaks detected. However, incubation of 0N4R-tau under condi-
tions that promote full auto-acetylation in the presence of acetyl-CoA led to the accumulation
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Fig 2. Tau auto-acetylation promotes tau-K18 and full-length tau fragmentation. A)Recombinant full length tau (0N4R) or tau-K18 containing only the
MTBR repeats were incubated in the presence of CoA or acetyl-CoA for 1 day and reaction products were analyzed by analyzed by SDS-PAGE and
Coomassie staining. The fold increase in acetyl-CoA-induced tau-K18 fragments is quantified in (B) and the percent remaining full-length 0N4R-tau is
quantified in (C), which resulted from N = 3 independent experimental replicates. Double asterisks (**) represent p-value 0.05 using student t-test. D) A
time-course analysis of tau-K18 fragmentation was performed in the presence of CoA or acetyl-CoA at the indicated time-points from 0–7 days and tau
fragment formation was quantified in (E). F) Size-exclusion chromatography (SEC) was used to measure tau fragments generated in the absence of cofactor,
or in the presence of CoA or acetyl-CoA. Full-length 0N4R tau protein eluted ~ 7.70 min while lower molecular weight tau fragments were detected as slower
eluting protein peaks at ~8.60 and ~10.18 min, which are highlighted by the black arrows.G) A sequential tau deletion library containing 10-residue deletions
spanning the 126 amino acid tau-K18 fragment (tau-K18Δ1- tau-K18Δ13), or tau cysteine mutants lacking one (C291A or C322A) or both (C291/322A)
cysteines were incubated in the presence of CoA or acetyl-CoA for 1 day and analyzed by SDS-PAGE and Coomassie staining. We note that purified tau-
K18Δ5 was unstable and therefore was not included in this analysis.
doi:10.1371/journal.pone.0158470.g002
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of distinct N- and C-terminal tau fragments eluting at ~8.60 and ~10.18 min (Fig 2F, see black
arrows denoting tau fragments), consistent with the acetylation-induced generation of low
molecular weight tau fragments.
Since tau fragmentation has been previously noted in vitro [26], we considered the possibil-
ity that acetylation could induce intrinsic auto-cleavage events resulting in production of tau
fragments. To map the residues required for tau proteolysis, we used a tau-K18 deletion/muta-
tion panel of proteins previously generated [9], which contains sequential 10-residue deletions
in tau-K18 (referred to as K18Δ1- K18Δ13) as well as single and double cysteine mutants
(C291/C322) that impair tau auto-acetylation. While none of the internal deletion proteins
fully abrogated tau fragmentation in a 1 day in vitro acetylation reaction, a cysteine-less tau-
K18 protein containing C!A substitutions at both C291 and C322 (2CA) was sufficient to
abrogate acetylation-induced fragmentation (Fig 2G).
We therefore generated a panel of cysteine mutant tau proteins and evaluated their ability
to undergo acetylation-induced fragmentation. Mutation of both C291 and C322 led to
impaired auto-acetylation at residue K280 (Fig 3A), and also dramatically impaired the ability
of 4R tau-K18 (2CS) and 3R tau-K19 (single C322S) to generate fragments (Fig 3B). Quantifi-
cation of these results showed that cysteine mutants completely eliminated the ~10-fold
increase in acetylation-induced fragmentation (Fig 3C). Further confirming the cysteine-
dependent fragmentation of full-length tau, the formation of ~17 and 12 kDa fragments pro-
duced by 0N4R-tau auto-acetylation was abrogated by cysteine mutations (Fig 3D, see 0N4R-
2CS). Since mutations of internal tau cysteines prevented tau fragmentation, these results sug-
gest that the observed auto-proteolytic activity is intrinsic to the tau proteins themselves rather
than any extraneous non-tau proteases present within the acetylation reactions. We nonethe-
less considered the possibility that other tau protease activities could be present. However, tau
cleavage with increasing concentrations of calpain, a well-characterized and robust tau protease
[27], generated an entirely distinct pattern of N- and C-terminal tau fragments (S1 Fig). Specif-
ically, calpain generated prominent ~ 15 kDa N-terminal and ~ 25 kDa C-terminal fragments,
suggesting that tau itself possesses a unique auto-proteolytic activity compared to that observed
with other tau proteases.
Further supporting the role of tau cysteines, the irreversible cysteine blocking agents iodoace-
tamide (IA) and N-ethylmaleimide (NEM) were sufficient to prevent fragmentation of tau-K18
(Fig 3E) and 0N4R-tau (Fig 3F) proteins induced by incubation with acetyl-CoA, suggesting free
thiol groups mediate acetylation-induced tau fragmentation. Interestingly, only irreversible cyste-
ine protease inhibitors were effective, as the reversible cysteine or serine protease inhibitors chy-
mostatin, ALLN, and antipain did not prevent acetylation-induced tau proteolysis (Fig 3F). We
note that the low molecular weight ~17 and 12 kDa fragments are indeed derived from the tau
C-terminus, since immunoblotting analysis using T46 and K9JA antibodies (detecting the
extreme C-terminus and C-terminal MTBR epitopes, respectively) were strongly immunoreac-
tive with both tau fragments (Fig 3F). Finally, to further support the role for tau cysteines in this
auto-catalytic process, we tested whether oxidative reaction conditions lacking the reducing
agent dithiothreitol (DTT), which favor cysteine disulfide cross-linking, are sufficient to impair
tau auto-actetylation. Indeed, omitting DTT led to slightly reduced tau auto-acetylation of either
full-length 2N4R-tau or tau-K18 proteins, as assessed by pan-[14C]-acetyl-CoA labeling (Fig 3G).
Tau auto-proteolytic cleavage induced by acetyl-CoA maps to within the
2nd and 4th MTBR
In order to map the acetylation-induced cleavage sites, larger scale reactions containing full-
length tau isoforms were auto-acetylated (Fig 4A). Full-length 4R-tau isoforms containing both
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Fig 3. Tau auto-acetylation induced fragmentation requires tau cysteines within the MTBR region. A) Tau-K18 or a cysteine-less mutant containing
C!S substitutions at C291 and C322 were incubated in vitro in acetylation reactions and analyzed by western blotting to examine auto-acetylation using ac-
K280 and total tau antibodies (percent ac-K280 immunoreactivity was determined as a ratio of total tau). B) Tau-K18, tau-K19, and their corresponding
cysteine to serine mutants were incubated with CoA or acetyl-CoA and analyzed by SDS-PAGE and Coomassie staining. Tau-K18 and tau-K19 generated
low molecular weight smears (referred to as LMW fragments). C) The fold induction of acetyl-CoA-induced fragmentation was quantified from wild-type and
cysteine mutant tau-K18 proteins. Note, cysteine mutants completely abolished tau-K18 fragment production. D) Acetylation of full-length 0N4R-tau
generated a range of N- and C-terminal tau fragments highlighted by black arrows that were reduced with the 0N4R-2CSmutant. E-F) Tau-K18 or full-length
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cysteines (C291 and C322) generated both ~17 and 12 kDa fragments, while 3R-tau isoforms
containing only C322 generated only the 12 kDa fragment, implying that tau cysteine residues
direct the cleavage specificity towards one or both C-terminal fragments. Both fragments were
immunoprecipitated from reactions containing acetylated 0N4R tau using the C-terminal T46
antibody, and protein bands corresponding to the tau fragments were excised for analysis by
mass spectrometry. Analysis of extreme N-terminal peptides derived from each fragment iden-
tified 282LDLSNVQSK290 (2nd MTBR) at the start of the 17 kDa fragment and
341SEKLDFKDR349 (4th MTBR) at the start of the 12 kDa fragment (Fig 4B and 4C). Additional
efforts to N-terminally sequence the tau fragments were not successful. However, we note that
the experimentally determined cleavage sites based on our mass spectrometry analysis predicts
0N4R tau were incubated with acetyl-CoA in the absence or presence of the protease inhibitors chymostatin (CS), iodoacetamide (IA), N-ethylmaleimide
(NEM), ALLN, or Antipain (AP), and tau-K18 LMW tau fragments (E) or the 17/12 kDa fragments generated by 0N4R-tau (F) were analyzed by SDS-PAGE
and Coomassie staining or immunoblotting using C-terminal T46 and K9JA tau antibodies.G) Tau proteins were incubated in acetylation reactions in the
absence or presence of 1mM DTT, radiolabeled with [14C]-acetyl-CoA, and analyzed by SDS-PAGE and Coomassie staining followed by autoradiography
and phosphorimaging.
doi:10.1371/journal.pone.0158470.g003
Fig 4. Acetylation-induced tau ~17 and ~12 kDa fragments map to the 2nd and 4th MTBR domains, respectively. A) Large-scale
2N4R, 0N4R, 2N3R, or 0N3R tau proteins were incubated with CoA or acetyl-CoA and analyzed by Coomassie staining to detect tau
fragments by Coomassie staining. Using large scale reactions as input, C-terminal fragments were immunprecipitated using anti-tau T46
antibodies and subject to mass spectrometry analysis. B) Extreme N-terminal peptides were mapped by mass spectrometry and were
localized to the start of the 2nd (17 kDa fragment) and 4th (12kDa fragment) MTBR, and the peptide spectra matching these extreme N-
terminal sequences are depicted in (C).
doi:10.1371/journal.pone.0158470.g004
Tau Acetylation Promotes Fragmentation
PLOS ONE | DOI:10.1371/journal.pone.0158470 July 6, 2016 11 / 19
molecular masses of 16.9 and 10.7 kDa C-terminal fragments, which is in close agreement with
the observed ~17 and 12 kDa fragments by western and SDS-PAGE gel analysis. Thus, our
results indicate that acetylation-induced cleavage requires tau catalytic cysteine residues,
thereby generating larger tau N-terminal fragments and their corresponding ~17 and ~12 kDa
C-terminal fragments containing portions of the MTBR domains.
To assess the specificity of acetyl-CoA in mediating tau auto-proteolytic cleavage, we per-
formed reactions with the related acyl-CoA derivatives butyryl-CoA and propionyl-CoA,
which are similar but slightly longer than acetyl-CoA and also capable of modifying target
lysines via butyrylation and propionylation reactions, potentially linking cellular metabolic
processes to acylation of target lysines [28–30]. To determine whether tau proteins are indeed
subject to modification by these other short chain CoAs, in vitro reactions containing propio-
nyl-CoA and butyryl-CoA derivatives were analyzed by mass spectrometry and modified
lysines detected by +56 (propionylation) or +70 (butyrylation) mass additions were identified
(S1 Table) within the 4-repeat containing tau-K18 sequence (Fig 5A, modified lysine residues
Fig 5. Tau auto-acetylation induced fragmentation shows specificity for acetyl-CoA compared to
longer acyl-CoA derivatives. A) Tau-K18 or the cysteine-less tau-K18-2CAmutant were incubated with a
panel of acyl-CoA derivatives of varying lengths (CoA, acetyl-CoA, butyryl-CoA, and propionyl-CoA) and
acylated tau proteins were analyzed by mass spectrometry to map butyrylated and propionylated tau lysine
residues. The tau-K18 schematic illustrates the positions corresponding to lysine butyrylation (+70) and
lysine propionylation (+56) sites that were detected within the 4-repeat MTBR. Positively identified lysines
(K’s) are bolded and underlined (see also S1 Table). B)Modified tau proteins were analyzed by Coomassie
staining to assess tau fragmentation. We note that tau fragmentation is cysteine-dependent and occurs most
readily with acetyl-CoA substrate compared to longer acyl-CoA derivatives.
doi:10.1371/journal.pone.0158470.g005
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are underlined). Many of the identified lysine residues are also acetylation targets [3, 5], sug-
gesting common overlap among acetylated, butyrylated, and propionylated acceptor lysines.
Analysis of all acylated tau-K18 proteins on Coomassie gels revealed that acetyl-CoA was able
to promote accumulation of low molecular weight tau fragments, which were not readily
observed with other acyl-CoA derivatives (Fig 5B). Thus, we conclude that, while larger acyl-
CoA derivatives are sufficient to modify tau via propionylation and butyrylation, they are not
as efficient as acetylation in generating auto-proteolytic processed tau fragments in vitro.
To examine tau proteolysis in cells, full-length 2N4R-tau was co-expressed with CBP to pro-
mote full tau acetylation, and we observed enhanced accumulation of C-terminal proteolytic
tau smearing with a panel of tau antibodies, which was dependent on CBP acetyltransferase
activity since this effect was reduced with an enzymatically inactive CBP-LD mutant (S2 Fig).
To examine if C-terminal tau fragments accumulate in AD brain, we sequentially extracted
frontal cortex brain tissue from control and AD cases (Fig 6). Western analysis of high salt
(HS) extracted brain homogenates containing soluble tau isoforms showed the expected migra-
tion pattern of human tau isoforms ~ 50–60 kDa, as detected with both N-terminal (tau5) and
C-terminal (T46) tau antibodies. Insoluble brain homogenates were generated from high-salt
insoluble material, which contained characteristic high molecular weight tau species corre-
sponding to insoluble tau aggregates. However, we also noted a ~ 24 kDa low molecular weight
tau fragment that was specifically detected in AD brains using the C-terminal T46 and K9JA
antibodies, but not the N-terminal tau5 antibody (Fig 6, see black arrowhead). Although we
found little evidence for ~17 or ~12 kDa C-terminal tau fragments in the late-stage AD brains
analyzed, the presence of a slightly larger ~ 24 kDa fragment is consistent with a recent study
[31], and supports the presence of cleaved C-terminal fragments containing a portion of the
tau MTBR that are detectable and stabilized in AD brain.
Discussion
In this study, we provide the first evidence that tau possesses an intrinsic auto-catalytic activity
that facilitates acetyl group transfer and self-fragmentation. Using biochemical, cellular, and
mass spectrometry approaches, we provide evidence for a catalytic mechanism in which 4R-
tau containing C291 and C322 mediates full acetylation-induced proteolysis, as either mutation
Fig 6. The generation of ~24 kDa but not ~17 and 12 kDa C-terminal tau fragments in AD brain.Gray matter from whole frontal cortex
(~5g) from control and AD brain was sequentially extracted with buffers of increasing strength (see brain extraction methods) to yield soluble
and insoluble tau fractions containing normal and aggregated tau species. Brain homogenates were analyzed by immunoblotting using N-
terminal (tau5) or C-terminal (T46 and K9JA) antibodies. We note that none of the cases examined contained ~17/12 kDa LMW tau fragments,
however, we detected ~24 kDa C-terminal tau fragments indicated by the black arrow, which is consistent with a previous study [31].
doi:10.1371/journal.pone.0158470.g006
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or pharmacological blockade of cysteines prevents the auto-proteolytic cascade. Our study suggests
a potential link between acetylation and downstream tau processing, which may contribute to the
heterogeneous accumulation of N- and C-terminal tau fragments that have been widely detected
in mouse and human AD brain as well as CSF from a range of tauopathy patients [31–37].
While acetylation is an energetically favorable process that could be vulnerable to false posi-
tive identification of acetylated residues [19, 38], our results suggest that tau auto-acetylation is
a regulated process. The requirement for cysteines (Fig 3A) suggests a catalytic mechanism
involving an acetyl-cysteine intermediate and subsequent acetyl group transfer to lysine resi-
dues, similar to other cysteine-dependent acetyltransferases including members of the MYST
[18], NAT [39, 40], and YopJ families [41–43]. This contrasts with direct acetylation of targeted
lysine residues mediated by CBP/p300. Secondly, we observed that auto-acetylation does not
uniformly occur on lysines spanning the tau protein, but rather showed site-specificity within
the lysine-rich MTBR domain (Fig 1). Previous studies suggest that auto-acetylation of cellular
substrates can occur prominently at basic stretches of lysine residues, of which the tau MTBR
could be an ideal candidate [21]. Thus, when free in solution, the tau MTBR could undergo
cysteine-dependent auto-acetylation in the presence of physiological concentrations of acetyl-
CoA. This activity may be suppressed when tau is bound to tubulin or MTs, but activated upon
tau dissociation during pathological conditions that abrogate tau-MT interactions, thus allow-
ing acetyl-CoA accessibility to free tau cysteines [9].
Although the exact mechanism by which tau auto-acetylation leads to fragmentation
remains unclear, an apparent non-enzymatic tau cleavage was previously observed by Wata-
nabe et al. using tau proteins incubated up to 90 days in vitro [26]. The authors identified
asparagine residues within the MTBR as the likely sites of auto-proteolytic cleavage, leading to
disappearance of full-length tau and concurrent high molecular weight tau smearing. Although
it is possible that acetylation accelerates a similar process to achieve rapid tau cleavage by ~ 1–2
days in our study, we find no evidence for high molecular weight smearing, at least at the time-
points and under the conditions employed in our study. Furthermore, the ~17 and ~12 kDa C-
terminal fragments generated from full-length tau are not suggestive of cleavage at asparagine
residues, or by fragmentation mediated by other tau proteases such as cathepsins or thrombin,
although we cannot rule out this possibility [44, 45]. Lastly, we find no evidence for contami-
nating proteases that may be present in our tau protein preparations (S1 Fig), which are fully
heat denatured and stringently purified using chromatography methods.
It is plausible that tau possesses intrinsic dual acetyltransferase/protease activities, in a man-
ner similar to bacterial effector proteins including YopJ family members that utilize cysteine-
dependent catalysis to facilitate either acetylation, proteolysis, or in some cases both activities
[41–43, 46]. Indeed, seemingly distinct cysteine protease and acetyltransferase activities within
the YopJ family are achieved by a common catalytic mechanism in which a catalytic triad of
residues facilitates either peptide hydrolysis or acetyl group transfer by employing a well con-
served charge relay system. In fact, some YopJ/HopZ members are reported to perform numer-
ous independent biochemical activities as either proteases or acetyltransferases [25]. Whether
tau possesses these catalytic functions in vivo in either an auto-regulatory manner or perhaps
directed towards non-tau substrates is not known. Our results indicate that different tau iso-
forms may possess different affinities to undergo auto-acetylation and proteolysis, with full-
length 4R-tau isoforms showing the most robust acetylation and production of both 17 and 12
kDa C-terminal fragments, while 3R-tau produced only the 12 kDa fragment (Fig 4A) [9]. In
addition, the exact function for tau N-terminal inserts has not been fully elucidated. Our data
suggest a potential inhibitory role for these domains in tau acetylation, as 0N4R tau isoforms
showed the most robust ac-K163 immunoreactivity, implying that N-terminal repeats may sig-
nificantly influence tau acetylation status.
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Since tau auto-acetylation occurs via a cysteine-dependent mechanism, conceivably, more
specific and less toxic compounds than NEM and IA (Fig 3D and 3E) that engage tau free cys-
teines may represent therapies to prevent auto-acetylation and downstream cleavage. In this
regard, methylene blue [47–54], and more recently 1,2-dihydrobenzene [55], were shown to
interact with tau cysteines and also alleviated cognitive deficits in tau transgenic mouse models.
Whether these compounds act via inhibition of tau auto-acetylation remains unknown. If so,
inhibition of tau acetylation could provide a simple rationale for why cysteine interacting com-
pounds may confer neuroprotection against tau-mediated toxicity.
Based on our results, we hypothesized that acetylation-induced tau C-terminal fragments
containing portions of the MTBR might accumulate in AD brain and potentially seed tau
aggregation or alter synaptic signaling, for example by modulating the recently described
KIBRA protein leading to memory loss [7]. Our analysis in AD brain detected the presence of a
~ 24 kDa C-terminal tau fragments, similar to that observed recently [31], implying that
smaller tau fragments< 24 kDa are either below our detection sensitivity or that only larger
MTBR fragments accumulate in AD brain. We cannot exclude the possibility that ~17 and/or
~12 kDa fragments are indeed generated in vivo, but perhaps further processed by additional
modifications (e.g. phosphorylation, ubiquitination) to yield slightly larger molecular mass
fragments. Alternatively, smaller C-terminal tau fragments could be targeted for degradation
in vivo. In this regard, we note that mass spectrometry analysis of the ~12 kDa tau fragment
identified an extreme N-terminal sequence 341SEKLDFKDR349 that is immediately adjacent to
a putative recognition motif for chaperone-mediated autophagy (CMA), 336QVEVK340 [56].
Thus, it is conceivable that tau auto-proteolysis exposes a putative CMA targeting sequence as
a clearance mechanism to degrade potentially toxic tau fragments, a process that may become
impaired in tauopathies. Future experiments in cell-based models could clarify whether MTBR
fragments accumulate intracellularly or perhaps become secreted, and whether autophagy is
activated in response to tau auto-proteolytic activity. In addition, efforts to analyze AD brains
at different Braak stages could further clarify whether tau fragmentation occurs earlier in AD
pathogenesis. If so, fragments may be generated continually but targeted for degradation due
to their potential for toxicity.
In summary, we provide evidence for a novel acetylation-induced auto-proteolytic cascade
that generates N- and C-terminal tau fragments with potential implications for normal tau
physiology and its pathological aggregation. Future efforts to characterize the disease relevance
of tau auto-regulation could provide unique opportunities to directly modulate tau catalytic
functions as a new therapeutic avenue for AD and other tauopathies. Tau auto-proteolytic frag-
mentation could also provide opportunities for biomarker discovery in tauopathies character-
ized by the accumulation of tau fragments in CSF and other patient biofluids.
Supporting Information
S1 Fig. Calpain-mediated tau proteolysis in vitro. Full-length 2N4R tau proteins were incu-
bated with increasing concentrations of recombinant calpain-2 (0-.5U enzyme/reaction). Reac-
tions containing calpain-induced tau fragments were analyzed by immunoblotting using a
panel of tau antibodies detecting N-terminal (T14 and tau-5 antibodies) or C-terminal (K9JA
and T46) tau epitopes. The calpain-mediated fragmentation patterns defined by the 15 kDa N-
terminal fragment and 25 kDa C-terminal fragment are distinct from tau auto-acetylation
induced fragmentation (Fig 2).
(TIF)
S2 Fig. Acetylation-induced tau proteolysis in cultured cells. CBP-catalyzed tau acetylation
was performed in co-transfected QBI-293 cells. Cell lysates were analyzed by tau
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immunoblotting using T46, K9JA, and tau-5 antibodies. Proteolytic tau low molecular weight
smears were observed upon full tau acetylation in the presence of wild-type CBP, but were
reduced with an enzymatically inactive CBP mutant (CBP-LD).
(TIF)
S1 Table. Mass spectrometry-based identification of sites of tau propionylation and butyry-
lation within the MTBR. Tau in vitro acylation reactions were performed for 1hr at 37° using
propionyl-CoA and butyryl-CoA, slightly longer acyl-coA derivatives compared to acetyl-CoA,
and 1.0 μg reaction products were resolved by gel elecrophoresis and analyzed by mass spec-
trometry (see methods). Unambiguously modified lysines were identified and sorted by loca-
tion within the tau-K18 protein sequence. The identified lysines shown in column 2
correspond to lysines that are underlined in Fig 5A.
(XLS)
Acknowledgments
We thank Dr. Virginia Lee and Dr. Kurt Brunden for critical reading of this manuscript. We
also thank Dr. Jing Guo, Dr. David Hurtado, and Dr. James Soper for helpful and insightful
discussions.
Author Contributions
Conceived and designed the experiments: TJC. Performed the experiments: TJC BHC AWH
MJ CXY. Analyzed the data: TJC BHC AWHMJ. Contributed reagents/materials/analysis
tools: TJC MJ CXY. Wrote the paper: TJC BHC.
References
1. Andreadis A, BrownWM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry.
1992; 31(43):10626–33. PMID: 1420178
2. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of humanmicrotu-
bule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's dis-
ease. Neuron. 1989; 3(4):519–26. PMID: 2484340
3. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhib-
its its function and promotes pathological tau aggregation. Nature communications. 2011; 2:252. doi:
10.1038/ncomms1255 PMID: 21427723
4. Irwin DJ, Cohen TJ, GrossmanM, Arnold SE, Xie SX, Lee VM, et al. Acetylated tau, a novel pathologi-
cal signature in Alzheimer's disease and other tauopathies. Brain. 2012; 135(Pt 3):807–18. doi: 10.
1093/brain/aws013 PMID: 22366796
5. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, SeeleyWW, et al. Acetylation of tau inhibits its
degradation and contributes to tauopathy. Neuron. 2010; 67(6):953–66. doi: 10.1016/j.neuron.2010.08.
044 PMID: 20869593
6. Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, et al. Critical role of acetylation in tau-mediated neu-
rodegeneration and cognitive deficits. Nat Med. 2015; 21(10):1154–62. doi: 10.1038/nm.3951 PMID:
26390242
7. Tracy TE, Sohn PD, Minami SS, Wang C, Min SW, Li Y, et al. Acetylated Tau Obstructs KIBRA-Medi-
ated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. Neuron. 2016;
90(2):245–60. doi: 10.1016/j.neuron.2016.03.005 PMID: 27041503
8. Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, et al. Tau post-transla-
tional modifications in wild-type and human amyloid precursor protein transgenic mice. Nature neuro-
science. 2015; 18(8):1183–9. doi: 10.1038/nn.4067 PMID: 26192747
9. Cohen TJ, Friedmann D, Hwang AW, Marmorstein R, Lee VM. The microtubule-associated tau protein
has intrinsic acetyltransferase activity. Nat Struct Mol Biol. 2013; 20(6):756–62. doi: 10.1038/nsmb.
2555 PMID: 23624859
Tau Acetylation Promotes Fragmentation
PLOS ONE | DOI:10.1371/journal.pone.0158470 July 6, 2016 16 / 19
10. Kamah A, Huvent I, Cantrelle FX, Qi H, Lippens G, Landrieu I, et al. Nuclear magnetic resonance analy-
sis of the acetylation pattern of the neuronal Tau protein. Biochemistry. 2014; 53(18):3020–32. doi: 10.
1021/bi500006v PMID: 24708343
11. Karanam B, Jiang L, Wang L, Kelleher NL, Cole PA. Kinetic and mass spectrometric analysis of p300
histone acetyltransferase domain autoacetylation. The Journal of biological chemistry. 2006; 281
(52):40292–301. PMID: 17065153
12. Lu L, Li L, Lv X, Wu XS, Liu DP, Liang CC. Modulations of hMOF autoacetylation by SIRT1 regulate
hMOF recruitment and activities on the chromatin. Cell Res. 2011; 21(8):1182–95. doi: 10.1038/cr.
2011.71 PMID: 21502975
13. Wang J, Chen J. SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. The Jour-
nal of biological chemistry. 2010; 285(15):11458–64. doi: 10.1074/jbc.M109.087585 PMID: 20100829
14. Yang C, Wu J, Sinha SH, Neveu JM, Zheng YG. Autoacetylation of the MYST lysine acetyltransferase
MOF protein. The Journal of biological chemistry. 2012; 287(42):34917–26. doi: 10.1074/jbc.M112.
359356 PMID: 22918831
15. Yang C, Wu J, Zheng YG. Function of the active site lysine autoacetylation in tip60 catalysis. PloS one.
2012; 7(3):e32886. doi: 10.1371/journal.pone.0032886 PMID: 22470428
16. Yuan H, Rossetto D, Mellert H, DangW, Srinivasan M, Johnson J, et al. MYST protein acetyltransfer-
ase activity requires active site lysine autoacetylation. EMBO J. 2012; 31(1):58–70. doi: 10.1038/
emboj.2011.382 PMID: 22020126
17. Dupret JM, Grant DM. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase
expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of
polymorphic human NAT2. The Journal of biological chemistry. 1992; 267(11):7381–5. PMID: 1559981
18. Yan Y, Harper S, Speicher DW, Marmorstein R. The catalytic mechanism of the ESA1 histone acetyl-
transferase involves a self-acetylated intermediate. Nat Struct Biol. 2002; 9(11):862–9. PMID:
12368900
19. Dormeyer W, Ott M, Schnolzer M. Probing lysine acetylation in proteins: strategies, limitations, and pit-
falls of in vitro acetyltransferase assays. Mol Cell Proteomics. 2005; 4(9):1226–39. PMID: 15933374
20. Luo Y, Ma B, Nussinov R, Wei G. Structural Insight into Tau Protein's Paradox of Intrinsically Disor-
dered Behavior, Self-Acetylation Activity, and Aggregation. J Phys Chem Lett. 2014; 5(17):3026–31.
PMID: 25206938
21. Olia AS, Barker K, McCullough CE, Tang HY, Speicher DW, Qiu J, et al. Nonenzymatic Protein Acetyla-
tion Detected by NAPPA Protein Arrays. ACS Chem Biol. 2015; 10(9):2034–47. doi: 10.1021/
acschembio.5b00342 PMID: 26083674
22. Baeza J, Smallegan MJ, Denu JM. Site-specific reactivity of nonenzymatic lysine acetylation. ACS
Chem Biol. 2015; 10(1):122–8. doi: 10.1021/cb500848p PMID: 25555129
23. Ghanta S, Grossmann RE, Brenner C. Mitochondrial protein acetylation as a cell-intrinsic, evolutionary
driver of fat storage: chemical and metabolic logic of acetyl-lysine modifications. Crit Rev BiochemMol
Biol. 2013; 48(6):561–74. doi: 10.3109/10409238.2013.838204 PMID: 24050258
24. Wagner GR, Payne RM. Widespread and enzyme-independent Nepsilon-acetylation and Nepsilon-
succinylation of proteins in the chemical conditions of the mitochondrial matrix. The Journal of biological
chemistry. 2013; 288(40):29036–45. doi: 10.1074/jbc.M113.486753 PMID: 23946487
25. Lewis JD, Lee A, MaW, Zhou H, Guttman DS, Desveaux D. The YopJ superfamily in plant-associated
bacteria. Mol Plant Pathol. 2011; 12(9):928–37. doi: 10.1111/j.1364-3703.2011.00719.x PMID:
21726386
26. Watanabe A, HongWK, Dohmae N, Takio K, Morishima-Kawashima M, Ihara Y. Molecular aging of
tau: disulfide-independent aggregation and non-enzymatic degradation in vitro and in vivo. Journal of
neurochemistry. 2004; 90(6):1302–11. PMID: 15341514
27. Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y. Cleavage of Tau by calpain in Alzheimer's
disease: the quest for the toxic 17 kD fragment. Neurobiol Aging. 2011; 32(1):1–14. doi: 10.1016/j.
neurobiolaging.2010.09.008 PMID: 20961659
28. Chen Y, Sprung R, Tang Y, Ball H, Sangras B, Kim SC, et al. Lysine propionylation and butyrylation are
novel post-translational modifications in histones. Mol Cell Proteomics. 2007; 6(5):812–9. PMID:
17267393
29. Cheng Z, Tang Y, Chen Y, Kim S, Liu H, Li SS, et al. Molecular characterization of propionyllysines in
non-histone proteins. Mol Cell Proteomics. 2009; 8(1):45–52. doi: 10.1074/mcp.M800224-MCP200
PMID: 18753126
30. Zhang K, Chen Y, Zhang Z, Zhao Y. Identification and verification of lysine propionylation and butyryla-
tion in yeast core histones using PTMap software. Journal of proteome research. 2009; 8(2):900–6.
doi: 10.1021/pr8005155 PMID: 19113941
Tau Acetylation Promotes Fragmentation
PLOS ONE | DOI:10.1371/journal.pone.0158470 July 6, 2016 17 / 19
31. Matsumoto SE, Motoi Y, Ishiguro K, Tabira T, Kametani F, Hasegawa M, et al. The twenty-four KDa C-
terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.
Human molecular genetics. 2015; 24(22):6403–16. doi: 10.1093/hmg/ddv351 PMID: 26374846
32. Arai T, Ikeda K, Akiyama H, Nonaka T, Hasegawa M, Ishiguro K, et al. Identification of amino-terminally
cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration.
Annals of neurology. 2004; 55(1):72–9. PMID: 14705114
33. Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL, Yang L, et al. Tau transgenic mice as models
for cerebrospinal fluid tau biomarkers. Journal of Alzheimer's disease: JAD. 2011; 24 Suppl 2:127–41.
doi: 10.3233/JAD-2011-110161 PMID: 21422517
34. Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, et al. Characterization
of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PloS one. 2013; 8(10):e76523. doi: 10.
1371/journal.pone.0076523 PMID: 24116116
35. Sokolow S, Henkins KM, Bilousova T, Gonzalez B, Vinters HV, Miller CA, et al. Pre-synaptic C-terminal
truncated tau is released from cortical synapses in Alzheimer's disease. Journal of neurochemistry.
2015; 133(3):368–79. doi: 10.1111/jnc.12991 PMID: 25393609
36. Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, et al. Divergent CSF tau alterations
in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. Journal of neurol-
ogy, neurosurgery, and psychiatry. 2015; 86(3):244–50. doi: 10.1136/jnnp-2014-308004 PMID: 24899730
37. Wray S, Saxton M, Anderton BH, Hanger DP. Direct analysis of tau from PSP brain identifies new phos-
phorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding
repeats. Journal of neurochemistry. 2008; 105(6):2343–52. doi: 10.1111/j.1471-4159.2008.05321.x
PMID: 18315566
38. Dormeyer W, Dorr A, Ott M, Schnolzer M. Acetylation of the HIV-1 Tat protein: an in vitro study. Anal
Bioanal Chem. 2003; 376(7):994–1005. PMID: 12904943
39. Payton M, Mushtaq A, Yu TW,Wu LJ, Sinclair J, Sim E. Eubacterial arylamine N-acetyltransferases—
identification and comparison of 18 members of the protein family with conserved active site cysteine,
histidine and aspartate residues. Microbiology. 2001; 147(Pt 5):1137–47. PMID: 11320117
40. Sinclair JC, Sandy J, Delgoda R, Sim E, Noble ME. Structure of arylamine N-acetyltransferase reveals
a catalytic triad. Nat Struct Biol. 2000; 7(7):560–4. PMID: 10876241
41. Mittal R, Peak-Chew SY, Sade RS, Vallis Y, McMahon HT. The acetyltransferase activity of the bacte-
rial toxin YopJ of Yersinia is activated by eukaryotic host cell inositol hexakisphosphate. The Journal of
biological chemistry. 2010; 285(26):19927–34. doi: 10.1074/jbc.M110.126581 PMID: 20430892
42. Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ, et al. Yersinia YopJ acetylates and inhib-
its kinase activation by blocking phosphorylation. Science. 2006; 312(5777):1211–4. PMID: 16728640
43. Paquette N, Conlon J, Sweet C, Rus F, Wilson L, Pereira A, et al. Serine/threonine acetylation of
TGFbeta-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proceed-
ings of the National Academy of Sciences of the United States of America. 2012; 109(31):12710–5. doi:
10.1073/pnas.1008203109 PMID: 22802624
44. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, et al. Inducible expression of
Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by
inhibitor drugs. The Journal of biological chemistry. 2006; 281(2):1205–14. PMID: 16246844
45. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau
fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Pro-
ceedings of the National Academy of Sciences of the United States of America. 2007; 104(24):10252–
7. PMID: 17535890
46. Ustun S, Bornke F. The Xanthomonas campestris type III effector XopJ proteolytically degrades protea-
some subunit RPT6. Plant Physiol. 2015; 168(1):107–19. doi: 10.1104/pp.15.00132 PMID: 25739698
47. Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M. Mechanistic basis of pheno-
thiazine-driven inhibition of Tau aggregation. Angew Chem Int Ed Engl. 2013; 52(12):3511–5. doi: 10.
1002/anie.201208290 PMID: 23401175
48. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, et al. Methylthioninium chloride
(methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012; 8
(4):609–22. doi: 10.4161/auto.19048 PMID: 22361619
49. Crowe A, James MJ, Lee VM, Smith AB 3rd, Trojanowski JQ, Ballatore C, et al. Aminothienopyrida-
zines and methylene blue affect Tau fibrillization via cysteine oxidation. The Journal of biological chem-
istry. 2013; 288(16):11024–37. doi: 10.1074/jbc.M112.436006 PMID: 23443659
50. Hochgrafe K, Sydow A, Matenia D, Cadinu D, Konen S, Petrova O, et al. Preventive methylene blue
treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuro-
pathol Commun. 2015; 3:25. doi: 10.1186/s40478-015-0204-4 PMID: 25958115
Tau Acetylation Promotes Fragmentation
PLOS ONE | DOI:10.1371/journal.pone.0158470 July 6, 2016 18 / 19
51. HosokawaM, Arai T, Masuda-Suzukake M, Nonaka T, Yamashita M, Akiyama H, et al. Methylene blue
reduced abnormal tau accumulation in P301L tau transgenic mice. PloS one. 2012; 7(12):e52389. doi:
10.1371/journal.pone.0052389 PMID: 23285020
52. O'Leary JC 3rd, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, et al. Phenothiazine-mediated
rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.
Mol Neurodegener. 2010; 5:45. doi: 10.1186/1750-1326-5-45 PMID: 21040568
53. Schirmer RH, Adler H, Pickhardt M, Mandelkow E. "Lest we forget you—methylene blue. . .". Neurobiol
Aging. 2011; 32(12):2325 e7-16.
54. Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, et al. Tau aggregation inhibitor
therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. Journal of Alzheimer's
disease: JAD. 2015; 44(2):705–20. doi: 10.3233/JAD-142874 PMID: 25550228
55. Soeda Y, Yoshikawa M, Almeida OF, Sumioka A, Maeda S, Osada H, et al. Toxic tau oligomer forma-
tion blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nature communica-
tions. 2015; 6:10216. doi: 10.1038/ncomms10216 PMID: 26671725
56. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, et al. Tau fragmentation,
aggregation and clearance: the dual role of lysosomal processing. Human molecular genetics. 2009;
18(21):4153–70. doi: 10.1093/hmg/ddp367 PMID: 19654187
Tau Acetylation Promotes Fragmentation
PLOS ONE | DOI:10.1371/journal.pone.0158470 July 6, 2016 19 / 19
